POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

M Bastos-Oreiro,A de las Heras,M Presa,MÁ Casado,C Pardo,V Martín-Escudero,A Sureda

Value in Health（2022）

引用 0|浏览1

暂无评分

摘要

The study aimed to assess the cost-effectiveness of axicabtagene ciloleucel (axi-cel) versus tisagenlecleucel (tisa-cel) for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥2 lines of systemic therapy in Spain.

查看译文

关键词

axicabtagene ciloleucel,treatment,b-cell,cost-effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要